Volume 26, Issue 2, Pages e2 (August 2017)

Slides:

Advertisements

Similar presentations

Mitoconfusion: Noncanonical Functioning of Dynamism Factors in Static Mitochondria of the Heart Moshi Song, Gerald W. Dorn Cell Metabolism Volume 21, Issue.

Advertisements

Making Proteins in the Powerhouse B. Martin Hällberg, Nils-Göran Larsson Cell Metabolism Volume 20, Issue 2, Pages (August 2014) DOI: /j.cmet

Functions of mitochondrial ISCU and cytosolic ISCU in mammalian iron-sulfur cluster biogenesis and iron homeostasis Wing-Hang Tong, Tracey A. Rouault Cell.

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.

The Metabolic Basis of Pulmonary Arterial Hypertension Gopinath Sutendra, Evangelos D. Michelakis Cell Metabolism Volume 19, Issue 4, Pages (April.

Lipin-1 Regulates Autophagy Clearance and Intersects with Statin Drug Effects in Skeletal Muscle Peixiang Zhang, M. Anthony Verity, Karen Reue Cell Metabolism.

Germline Energetics, Aging, and Female Infertility Jonathan L. Tilly, David A. Sinclair Cell Metabolism Volume 17, Issue 6, Pages (June 2013) DOI:

Oxygen Sensors at the Crossroad of Metabolism Julián Aragonés, Peter Fraisl, Myriam Baes, Peter Carmeliet Cell Metabolism Volume 9, Issue 1, Pages

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.

Yun Hyung Koog, Jin Su Lee, Hyungsun Wi

Figure 1. Consort flow diagram.

Copyright © 2002 American Medical Association. All rights reserved.

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

The ART of Lowering Ceramides

Shelley R. Salpeter, MD, FACP, Andrew J. Wall, MD, Nicholas S. Buckley

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Volume 14, Issue 2, Pages (August 2011)

Ghrelin—a new player in glucose homeostasis?

Acupuncture versus Sham Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Shaun Wen Huey Lee, MPharm, Men Long Liong, MD, Kah Hay Yuen, PhD, Wing.

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

A Randomized Controlled Trial of a Community-based Behavioral Counseling Program Craig A. Johnston, PhD, Stephanie Rost, MS, RD, Karen Miller-Kovach,

Volume 12, Issue 5, Pages (November 2010)

Volume 24, Issue 3, Pages (September 2016)

Volume 18, Issue 3, Pages (September 2013)

Antibiotic Exposure Promotes Fat Gain

Once Blind, Now We See GLP-1 Molecular Action

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

Volume 15, Issue 1, Pages (January 2012)

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo- controlled study Patrick M. Moriarty, MD, Eli M. Roth, MD, Adam.

Volume 23, Issue 3, Pages (March 2016)

Carmelo V. Venero, MD, Paul D. Thompson, MD, Antonio B. Fernandez, MD

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I Ruben A. Mesa, Srdan Verstovsek,

Susumu Takahashi, Kazuyoshi Okada, Mitsuru Yanai Kidney International

Treating Obesity? It's in the Bag!

Strict versus liberal target range for perioperative glucose in patients undergoing coronary artery bypass grafting: A prospective randomized controlled.

IL-6 Muscles In on the Gut and Pancreas to Enhance Insulin Secretion

Adrian Martineau The Lancet Respiratory Medicine

Branching Out for Detection of Type 2 Diabetes

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease:

The Stunned β Cell: A Brief History

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled.

Volume 154, Issue 5, Pages (November 2018)

Ian H. de Boer, Rajnish Mehrotra Kidney International

Volume 26, Issue 1, Pages e7 (July 2017)

Volume 26, Issue 2, Pages e2 (August 2017)

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Flow of Patients Through Trial

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients Ariel Israel, MD, PhD, Ehud Grossman, MD The.

Volume 18, Issue 3, Pages (September 2013)

Volume 368, Issue 9541, Pages (September 2006)

Volume 14, Issue 2, Pages (August 2011)

Issue Highlights Clinical Gastroenterology and Hepatology

Volume 6, Issue 1, Pages (July 2007)

VK2809 in NAFLD: a phase 2 study

Adipose Dendritic Cells Come Out of Hiding

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Treating Diabetes by Blocking a Vascular Growth Factor

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Volume 128, Issue 4, Pages (April 2005)

Hap1 and GABA: Thinking about food intake

© The Author(s) Published by Science and Education Publishing.

Presentation transcript:

Volume 26, Issue 2, Pages 343-352.e2 (August 2017) The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Juan Pablo Frias, Edward J. Bastyr, Louis Vignati, Matthias H. Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D. DiMarchi Cell Metabolism Volume 26, Issue 2, Pages 343-352.e2 (August 2017) DOI: 10.1016/j.cmet.2017.07.011 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 Trial Design Overview of trial design showing the three trial arms and the different trial periods. Cell Metabolism 2017 26, 343-352.e2DOI: (10.1016/j.cmet.2017.07.011) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 2 Participant Flow Diagram Numbers of patients initially screened, randomized, withdrawn, and included in the ITT analysis set for the three trial arms are depicted. The ITT analysis set is defined as all patients who were randomized and had evaluable measurement of the parameter of interest at baseline and at least one post-baseline visit. AE, adverse event; ITT, intention to treat; SAE, serious adverse event. Cell Metabolism 2017 26, 343-352.e2DOI: (10.1016/j.cmet.2017.07.011) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 3 Effect of NNC0090-2746 on HbA1c, Body Weight, and MTT Parameters Time course of mean (±SEM) change from baseline in HbA1c (A) and body weight (B) as well as plasma glucose (C and D) and C-peptide (E and F) responses during a meal tolerance test at baseline (Week 1) and Week 12. MTT, meal tolerance test. See also Figure S1. Cell Metabolism 2017 26, 343-352.e2DOI: (10.1016/j.cmet.2017.07.011) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 4 Effect of NNC0090-2746 on Adipose Biomarkers and Lipid Parameters Treatment ratios with 95% CI for fasting lipids from baseline to W13 (A) and for adipose biomarkers from baseline to W12 (B) with NNC0090-2746 compared to placebo. HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein. See also Figure S3. Cell Metabolism 2017 26, 343-352.e2DOI: (10.1016/j.cmet.2017.07.011) Copyright © 2017 Elsevier Inc. Terms and Conditions

Cell Metabolism 2017 26, 343-352.e2DOI: (10.1016/j.cmet.2017.07.011) Copyright © 2017 Elsevier Inc. Terms and Conditions